Sarepta Therapeutics (NASDAQ:SRPT) Upgraded at Royal Bank of Canada

Royal Bank of Canada upgraded shares of Sarepta Therapeutics (NASDAQ:SRPT) from a sector perform rating to an outperform rating in a report released on Monday morning, Marketbeat Ratings reports. They currently have $182.00 price target on the biotechnology company’s stock.

Several other research analysts also recently weighed in on the stock. Cantor Fitzgerald reissued a neutral rating and issued a $128.00 target price on shares of Sarepta Therapeutics in a research report on Friday, June 21st. Needham & Company LLC reissued a buy rating and issued a $235.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, June 27th. Citigroup downgraded shares of Sarepta Therapeutics from a buy rating to a neutral rating and lifted their target price for the stock from $172.00 to $176.00 in a research report on Wednesday, June 26th. Piper Sandler reissued an overweight rating and issued a $205.00 target price on shares of Sarepta Therapeutics in a research report on Monday, July 1st. Finally, SVB Leerink lifted their target price on shares of Sarepta Therapeutics from $165.00 to $230.00 and gave the stock an outperform rating in a research report on Monday, June 24th. Four analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and a consensus price target of $187.72.

Sarepta Therapeutics Stock Performance

Shares of SRPT opened at $142.24 on Monday. The firm’s 50 day moving average is $138.33 and its 200-day moving average is $130.38. The stock has a market capitalization of $13.44 billion, a P/E ratio of 1,293.09 and a beta of 0.89. The company has a debt-to-equity ratio of 1.18, a current ratio of 4.05 and a quick ratio of 3.44. Sarepta Therapeutics has a 12-month low of $55.25 and a 12-month high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.84. The company had revenue of $413.50 million for the quarter, compared to analysts’ expectations of $375.52 million. Sarepta Therapeutics had a net margin of 1.20% and a return on equity of 2.20%. The business’s revenue was up 63.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.44) EPS. Equities research analysts anticipate that Sarepta Therapeutics will post 3.76 EPS for the current fiscal year.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, insider Bilal Arif sold 7,859 shares of Sarepta Therapeutics stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $163.08, for a total value of $1,281,645.72. Following the completion of the sale, the insider now directly owns 21,261 shares in the company, valued at $3,467,243.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, insider Bilal Arif sold 7,859 shares of the business’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $163.08, for a total value of $1,281,645.72. Following the completion of the sale, the insider now directly owns 21,261 shares in the company, valued at $3,467,243.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Ryan Edward Brown sold 38,957 shares of the company’s stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $161.61, for a total transaction of $6,295,840.77. Following the transaction, the executive vice president now owns 17,129 shares of the company’s stock, valued at $2,768,217.69. The disclosure for this sale can be found here. Corporate insiders own 7.70% of the company’s stock.

Institutional Investors Weigh In On Sarepta Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of SRPT. Principal Securities Inc. bought a new stake in shares of Sarepta Therapeutics in the 4th quarter worth about $26,000. Mather Group LLC. acquired a new position in Sarepta Therapeutics during the 1st quarter worth about $28,000. Riggs Asset Managment Co. Inc. lifted its position in Sarepta Therapeutics by 125.0% during the 1st quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock worth $29,000 after buying an additional 125 shares in the last quarter. Innealta Capital LLC acquired a new position in Sarepta Therapeutics during the 2nd quarter worth about $31,000. Finally, New Covenant Trust Company N.A. acquired a new position in Sarepta Therapeutics during the 1st quarter worth about $32,000. Institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.